Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a landscape of robust demand for its groundbreaking diabetes and obesity treatments,

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the overall commercial strategy for Kailera’s pipeline of GLP-1 candidates to treat obesity and related conditions.

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with an increase in online searches for obesity drugs, according to data published in JAMA Network Open.

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk's recent climb.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly and Company discovers ... and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug last month and lower-than-expected sales figures from Eli Lilly for two consecutive quarters,

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according to analysts from BMO Capital Markets.

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts cautioned certain aspects of the study may have inflated its performance.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday.